CLINICAL TRIALS PROFILE FOR DAYTRANA
✉ Email this page to a colleague
All Clinical Trials for Daytrana
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00434213 ↗ | Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA | Completed | Noven Therapeutics | Phase 4 | 2007-01-01 | This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks. |
| NCT00499863 ↗ | Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD | Completed | Noven Therapeutics | Phase 3 | 2007-07-01 | To assess the efficacy and safety of efficacy of MTS compared to placebo |
| NCT00501293 ↗ | Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD | Completed | Noven Therapeutics | Phase 3 | 2007-08-01 | To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD |
| NCT00506285 ↗ | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Completed | Shire | Phase 3 | 2007-06-01 | This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects. |
| NCT00506285 ↗ | Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD | Completed | University of Utah | Phase 3 | 2007-06-01 | This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects. |
| NCT00541346 ↗ | A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms | Completed | Mark L. Wolraich, M.D. | Phase 3 | 2007-09-01 | This is an open-label study of the efficacy of Daytrana (methylphenidate transdermal system) for the treatment of attention and behavioral symptoms in children with Autism Spectrum Disorders. Twenty patients will be enrolled and treated with 10-30 mg of Daytrana for a total of eight weeks. Changes in core hyperactivity, impulsivity, and inattention symptoms, autism spectrum symptoms and functional outcomes will be assessed. Acceptability of the transdermal route of administration in this population will also be assessed. The researchers hypothesize that Daytrana is a safe and effective medication for children with Autism Spectrum Disorders who have symptoms of inattention, hyperactivity and impulsivity. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Daytrana
Condition Name
Clinical Trial Locations for Daytrana
Trials by Country
Clinical Trial Progress for Daytrana
Clinical Trial Phase
Clinical Trial Sponsors for Daytrana
Sponsor Name
